Jump Financial LLC raised its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 74.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 233,003 shares of the biopharmaceutical company’s stock after buying an additional 99,101 shares during the period. Jump Financial LLC’s holdings in Akebia Therapeutics were worth $883,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Voloridge Investment Management LLC purchased a new position in shares of Akebia Therapeutics during the first quarter worth $43,000. O Shaughnessy Asset Management LLC boosted its position in shares of Akebia Therapeutics by 26,137.5% during the second quarter. O Shaughnessy Asset Management LLC now owns 14,693 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 14,637 shares during the period. Bridgefront Capital LLC purchased a new position in shares of Akebia Therapeutics during the second quarter worth $65,000. Ameriprise Financial Inc. boosted its position in shares of Akebia Therapeutics by 17.3% during the first quarter. Ameriprise Financial Inc. now owns 20,497 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 3,018 shares during the period. Finally, XTX Topco Ltd purchased a new position in Akebia Therapeutics in the second quarter valued at $78,000. Institutional investors and hedge funds own 60.57% of the company’s stock.
NASDAQ:AKBA opened at $2.94 on Thursday. The firm has a market cap of $513.14 million, a PE ratio of -1.48 and a beta of 1.71. The stock has a fifty day moving average price of $2.80 and a 200 day moving average price of $3.10. Akebia Therapeutics, Inc. has a 12-month low of $2.09 and a 12-month high of $5.14. The company has a current ratio of 2.00, a quick ratio of 1.77 and a debt-to-equity ratio of 0.55.
Separately, Zacks Investment Research upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 4th.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.
Recommended Story: What is the Nikkei 225 index?
Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics, Inc. (NASDAQ:AKBA).
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.